TKIs beyond immunotherapy predict improved survival in advanced HCC.

Samantha ArmstrongTina RoyBhavana SinghMonika KulasekaranFatima ShaukatXue GengHongkun WangPetra PrinsReena C JhaMarion L HartleyAiwu Ruth He

Published in: Journal of cancer research and clinical oncology (2022)

We show that disease control predicts prolonged mOS and mPFS. Furthermore, TKI therapy administered after immunotherapy predicts prolonged mOS in patients with advanced HCC.

Keyphrases

quantum dots
room temperature
reduced graphene oxide
tyrosine kinase
transition metal
highly efficient
visible light
free survival
stem cells
bone marrow